Gotardo E, Torres L, Zaidan B, Gushiken L, Brito P, Leonardo F
Haematologica. 2024; 110(3):725-738.
PMID: 39568425
PMC: 11873698.
DOI: 10.3324/haematol.2024.286418.
Morrone K, Strumph K, Pisacano C, Briggs J, Zipper R, Patel B
Pediatr Blood Cancer. 2024; 72(1):e31378.
PMID: 39420509
PMC: 11584302.
DOI: 10.1002/pbc.31378.
Barnawi Z, Thomas R, Peddinti R, Abou Baker N
Children (Basel). 2024; 11(9).
PMID: 39334638
PMC: 11430294.
DOI: 10.3390/children11091106.
Torres L, Hidalgo A
Immunol Rev. 2022; 314(1):302-312.
PMID: 36251624
PMC: 10132504.
DOI: 10.1111/imr.13146.
Metaferia B, Cellmer T, Dunkelberger E, Li Q, Henry E, Hofrichter J
Proc Natl Acad Sci U S A. 2022; 119(40):e2210779119.
PMID: 36161945
PMC: 9546543.
DOI: 10.1073/pnas.2210779119.
Salubrinal induces fetal hemoglobin expression via the stress-signaling pathway in human sickle erythroid progenitors and sickle cell disease mice.
Lopez N, Li B, Palani C, Siddaramappa U, Takezaki M, Xu H
PLoS One. 2022; 17(5):e0261799.
PMID: 35639781
PMC: 9154101.
DOI: 10.1371/journal.pone.0261799.
To Give or Not to Give: RhD Immunoglobulin for an * Pregnant Woman with Sickle Cell Disease.
Juskewitch J, Tauscher C, Moldenhauer S, Schieber J, Jacob E, DiGuardo M
Transfus Med Hemother. 2021; 48(4):244-249.
PMID: 34539319
PMC: 8406349.
DOI: 10.1159/000512644.
Pain in sickle cell disease: current and potential translational therapies.
Sagi V, Mittal A, Tran H, Gupta K
Transl Res. 2021; 234:141-158.
PMID: 33711512
PMC: 8217144.
DOI: 10.1016/j.trsl.2021.03.007.
Efficient Clinical Counseling for Sickle Cell Disease.
Morrone K, Manwani D, Cabana M
J Natl Med Assoc. 2021; 113(4):382-387.
PMID: 33610309
PMC: 8368067.
DOI: 10.1016/j.jnma.2021.01.006.
Pyridoxamine: another vitamin for sickle cell disease?.
Telen M
Haematologica. 2020; 105(10):2348-2350.
PMID: 33054072
PMC: 7556650.
DOI: 10.3324/haematol.2020.257998.
Drug Therapies for the Management of Sickle Cell Disease.
Rai P, Ataga K
F1000Res. 2020; 9.
PMID: 32765834
PMC: 7388199.
DOI: 10.12688/f1000research.22433.1.
Curative vs targeted therapy for SCD: does it make more sense to address the root cause than target downstream events?.
Telen M
Blood Adv. 2020; 4(14):3457-3465.
PMID: 32722787
PMC: 7391143.
DOI: 10.1182/bloodadvances.2020001469.
The Evolving Pharmacotherapeutic Landscape for the Treatment of Sickle Cell Disease.
Ballas S
Mediterr J Hematol Infect Dis. 2020; 12(1):e2020010.
PMID: 31934320
PMC: 6951351.
DOI: 10.4084/MJHID.2020.010.
Why, Who, When, and How? Rationale for Considering Allogeneic Stem Cell Transplantation in Children with Sickle Cell Disease.
Bernaudin F
J Clin Med. 2019; 8(10).
PMID: 31546720
PMC: 6833062.
DOI: 10.3390/jcm8101523.
